Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + rebastinib
- Development stage
- Unknown
- Lead developer
- Deciphera Pharmaceuticals
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Fragment-Derived Small Molecules → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Paclitaxel + rebastinib is an investigational combination therapy consisting of the microtubule-stabilizing chemotherapeutic agent paclitaxel and the oral small molecule kinase inhibitor rebastinib. Paclitaxel disrupts cell division by stabilizing microtubules, leading to apoptosis in rapidly dividing cancer cells. Rebastinib is a potent and selective switch-control inhibitor of tunica interna endothelial cell kinase 2 (TIE2), a receptor tyrosine kinase involved in angiogenesis and tumor microenvironment regulation. The combination aims to enhance anti-tumor efficacy by targeting both tumor cells directly (paclitaxel) and the tumor vasculature/microenvironment (rebastinib). This regimen has been studied primarily in advanced or metastatic solid tumors, including HER2-negative metastatic breast cancer, endometrial cancer, platinum-resistant ovarian cancer, gynecological carcinosarcoma, triple-negative breast cancer (TNBC), and inflammatory breast cancer[1][2][3][4][5].
02
Targets
MicrotubuleTEK (Tie2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + rebastinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + rebastinib.